Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK2212836 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836. |
| Part B | EXPERIMENTAL | Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo. |
| Name | Type | Description |
|---|---|---|
| GSK2212836 | DRUG | Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation. |
Inclusion Criteria: * AST, ALT, alkaline phosphatase and bilirubin less than 1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Healthy as determined by a responsible and experienced physician, based on a medical evaluation including \[me...
GSK2212836 is an investigational small molecule being developed for cardiovascular disease. It is currently in Phase 1 clinical development and has been studied in a completed clinical trial involving patients with cardiovascular disease.
GSK2212836 is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for cardiovascular disease.
GSK2212836 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 clinical trial for the drug has been completed.
GSK2212836 has been studied in a completed Phase 1 clinical trial with the identifier NCT00996268. The trial was an open-label, single-dose, randomized, parallel group study followed by single-blind repeat dosing, conducted in the United States with 46 participants.
GSK2212836 is the primary name for this investigational drug. No alternative names have been reported for this compound in clinical development for cardiovascular disease.